anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a novel medical entity zero sample classification method based on a language model. The method converts the entity classification problem into a complete gap filling problem by constructing a query of a natural language; and then, solving the answer of the completed gap filling problem by using a pre-trained medical bert model to realize the classification of the zero sample. The method comprises the steps of starting from a pre-training medical bert model, and using a medical pre-training corpus to train the bert model to obtain the pre-training medical bert model. And then constructing a corresponding complete blank-filling template according to the entity category to be identified, and generating a complete blank-filling problem for each entity in each sentence in the entity classification problem test set by using the constructed complete blank-filling template. And predicting the probability value of each complete gap-filling problem by using a pre-trained medical bert model, and taking the category with the maximum probability value as the category corresponding to the entity. The method achieves 85.60 in CCKS2019 data set Precision, 85.60 in Recall and 85.60 in F-score.
Patients receive belantamab mafodotin IV over 30 minutes on day 1 of every other cycle, pomalidomide PO QD on days 1-21, and dexamethasone PO QD on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The cosmetic composition for making up keratin materials has an oily continuous phase and comprises at least one polyelectrolyte, at least one surfactant having an HLB of greater than or equal to 6 at 25[deg.]C and at least one dye. The cosmetic composition is characterized in that the polyelectrolyte is branched and/or cross-linked. The cosmetic composition has the oily continuous phase, exhibits good water resistance and is readily removed. The cosmetic composition uses the combination of at least the one polyelectrolyte and of at least the one surfactant having an HLB of greater than or equal to 6 at 25[deg.]C for preparing a cosmetic composition for making up and/or for non-therapeutic care of the keratin materials. An associated cosmetic process is provided.
A composite photothermal material, a preparation method therefor and the use thereof. The composite photothermal material comprises a two-dimensional photothermal material matrix. The two-dimensional photothermal material matrix is two-dimensional antimonene, and the two-dimensional antimonene is loaded with nano silver particles. The preparation method thereof comprises the steps of: providing the two-dimensional antimonene; forming nano silver particles on the two-dimensional antimonene to achieve the loading of the nano silver particles on the two-dimensional antimonene, so as to obtain the composite photothermal material. In the composite photothermal material, the two-dimensional antimonene serves as a matrix of a bifunctional response platform, and achieves, together with nano silver particles, a photothermal/photodynamic synergistic treatment effect, which achieves a remarkable cancer treatment effect. The preparation method may ensure that the prepared composite photothermal material has a stable performance in terms of photothermal/photodynamic synergistic treatment, and the preparation method has a high efficiency and reduces the economic cost.
Metastatic breast-cancer is one of the major causes of death, due to remaining dormant cancer cells for several years. Rac1 is upregulated with cancer and stay elevated throughout the metastatic pathway to regulate the formation of lamellipodia and filopodia. This work developed peptide FGDWS as novel inhibitor targeting Rac1-Tiam1 binding site by in-silico as it was found to be the strongest interacting peptide with Rac1 at the Tiam binding site. The binding and inhibition study of peptide with Rac1 was performed by Surface plasmon resonance and MTT assay, respectively. Cell-migration, apoptotic assay and western-blot in breast-cancer cells were performed with FGDWS and in combination with Doxorubicin (Dox). Tumor regression experiment was done with mice model. The strong binding of FGDWS with Rac1 and reduction of cell-viability were observed in breast-cancer cell-lines. The cell-migration was suppressed, and higher regression were obtained in synergy group. The apoptotic effect of FGDWS alone and with Dox were detected by annexin-V via activating caspase3/7. The tumor size was reduced by the treatment of FGDWS and more reduced in combinatorial effect. The combinatorial effect of FGDWS-Dox may enhance the treatment efficacy without side-effects.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: what is offered is a biologically active substance showing 5-HT3-serotonin receptor antagonist properties, 1-piperidinopropyl-2-(4-fluorophenyl)imidazo[1,2-a]benzimidazole of formula I. The compound has been known as a local anaesthetic. There are shown evident 5-HT3-antagonist properties of the compound in the macromolar concentration equal to the reference preparation ondansetron with the compound of formula I being safer. ^ EFFECT: new properties of the compound can be used for creating the effective agents exhibiting antiemetic, anxiolytic and analgesic activities. ^ 2 cl, 2 tbl
Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to BIMZELX during pregnancy. For more information, healthcare providers or patients can contact the Organization of Teratology Information Specialists (OTIS) AutoImmune Diseases Study at 1-877-311-8972 or visit http://mothertobaby.org/pregnancy-studies/.

Risk Summary

Available data from case reports on BIMZELX use in pregnant women are insufficient to evaluate for a drug associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Transport of human IgG antibody across the placenta increases as pregnancy progresses and peaks during the third trimester; therefore, BIMZELX may be transmitted from the mother to the developing fetus (see Clinical Considerations). In an enhanced pre- and postnatal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of bimekizumab-bkzx during the period of organogenesis through parturition at doses up to 38 times the maximum recommended human dose (MRHD) (see Data).

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions: Because bimekizumab-bkzx may interfere with immune response to infections, risks and benefits should be considered prior to administering live vaccines to infants exposed to BIMZELX in utero. There are no data regarding infant serum levels of bimekizumab-bkzx at birth and the duration of persistence of bimekizumab-bkzx in infant serum after birth. Although a specific timeframe to delay live virus immunizations in infants exposed in utero is unknown, a minimum of 4 months after birth may be considered because of the half-life of the product.

Data

Animal Data: An enhanced pre- and postnatal developmental toxicity study was conducted in cynomolgus monkeys. Pregnant cynomolgus monkeys were administered subcutaneous doses of bimekizumab-bkzx of 20 or 50 mg/kg/week from gestation day 20 to parturition and the cynomolgus monkeys (mother and infants) were monitored for 6 months after delivery. No maternal toxicity was noted in this study. There were no treatment-related effects on growth and development, malformations, developmental immunotoxicology or neurobehavioral development. The no observed adverse effect level (NOAEL) for both maternal and developmental toxicity was identified as 50 mg/kg/week (38 times the MRHD, based on mg/kg comparison of 1.33 mg/kg/week administered as a 320 mg dose to a 60 kg individual once every 4 weeks).
Adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis that have failed stereotactic radiosurgery treatment will be screened. They will sign consent and complete screening procedures. Each patient will be scheduled to undergo biopsy and LITT treatment. Within two weeks of surgery, patients will begin receiving pembrolizumab every three weeks. Pembrolizumab infusions will continue until brain met recurrence per RANO for Brain Mets or up to two years, whichever comes first. Blood samples will be collected for immune monitoring. Tumor tissue will be collected for immune and genomic studies. Approximately 21 patients will be enrolled to accrue 15 evaluable subjects. Patients will be followed for survival data for one year or until death, whichever comes first.
BACKGROUND: Ibogaine is a plant-derived alkaloid that has been used for thousands of years in rites of passage and spiritual ceremonies in West-Central Africa. In the West, it has primarily been used and studied for its anti-addictive properties and more recently for other neuropsychiatric indications, including post-traumatic stress disorder, depression, anxiety, and traumatic brain injury.
AREAS OF UNCERTAINTY: Ibogaine requires careful patient screening and monitoring because of significant safety issues. There is potential for cardiotoxicity (prolonged QT interval); without rigorous screening, fatal arrhythmias may occur. However, preliminary research suggests that co-administration of ibogaine with magnesium may mitigate cardiotoxicity. Additionally, ibogaine may have dangerous interactions with opiates, so patients who receive ibogaine treatment for opioid use disorder must withdraw from long-acting opioids. Other potential concerning effects of ibogaine include rare incidences of mania or psychosis. Anticipated transient effects during ibogaine treatment can include ataxia, tremors, and gastrointestinal symptoms.
THERAPEUTIC ADVANCES: Robust effects after a single treatment with ibogaine have been reported. In open-label and randomized controlled trials (RCTs), ibogaine reduces heroin and opioid cravings by upwards of 50%, up to 24 weeks after the treatment. An observational study of 30 Special Operations Forces veterans with mild traumatic brain injury reported that 86% were in remission from post-traumatic stress disorder, 83% from depression, and 83% from anxiety, one month after a single-dose ibogaine treatment.
LIMITATIONS: Although there are several observational and open-label studies, there is only a single double-blind, placebo-controlled RCT on ibogaine. More RCTs with large sample sizes must be conducted to support ibogaine's safety and efficacy.
CONCLUSIONS: Given the promising preliminary findings, ibogaine could potentially fill a much-needed gap in treatments for challenging conditions, including opioid dependence. Ibogaine's remarkable effects in traditionally treatment-resistant, combat-exposed individuals hints at its potential in broader populations with physical and psychological trauma.
The pooled results from three pharmacokinetic studies in 88 adult atopic dermatitis patients indicate that tacrolimus is minimally absorbed after the topical application of tacrolimus ointment. Peak tacrolimus blood concentrations ranged from undetectable to 20 ng/mL after single or multiple doses of 0.03% and 0.1% tacrolimus ointment, with 85% (75/88) of the patients having peak blood concentrations less than 2 ng/mL. In general as treatment continued, systemic exposure declined as the skin returned to normal. In clinical studies with periodic blood sampling, a similar distribution of tacrolimus blood levels was also observed in adult patients, with 90% (1253/1391) of patients having a blood concentration less than 2 ng/mL. 

The absolute bioavailability of tacrolimus from tacrolimus ointment in atopic dermatitis patients is approximately 0.5%. In adults with an average of 53% BSA treated, exposure (AUC) of tacrolimus from tacrolimus ointment is approximately 30-fold less than that seen with oral immunosuppressive doses in kidney and liver transplant patients. 

Mean peak tacrolimus blood concentrations following oral administration (0.3 mg/kg/day) in adult kidney transplant (n=26) and liver transplant (n=17) patients are 24.2±15.8 ng/mL and 68.5±30.0 ng/mL, respectively. The lowest tacrolimus blood level at which systemic effects (e.g., immunosuppression) can be observed is not known. Systemic levels of tacrolimus have also been measured in pediatric patients (see Special Populations: Pediatrics).
This is a prospective, multicenter, randomized controlled clinical trial comparing different doses of rosuvastatin in patients with acute coronary syndrome post drug-eluting stents implantation. In total, the investigators plan to recruit 80 patients with acute coronary syndrome (but no acute ST-segment elevation myocardial infarction) participating in the study. After signing informed consent form, the patients will be randomly assigned into high dose rosuvastatin and low dose rosuvastatin groups (40 cases in each group) by a computer generated random sequence table on a ratio of 1:1. Patients in the high-dose group will be prescribed rosuvastatin calcium of 20mg/d at least 6 months post index procedure, while patients in low dose group will have rosuvastatin calcium of 10mg/d, also at least 6 months. Additionally, all patients will receive dual antiplatelet therapy (oral aspirin 100mg qd, clopidogrel 75mg qd or ticagrelor 90 mg bid). Clinical follow up (telephone or out-patient follow-up) will be scheduled at 30 days, 6 months, 1 year, 2 years and 3 years. Optical coherence tomography examinations will be performed at 6 months. Neointimal hyperplasia, stent strut coverage and thin cap fibroatheroma are primary observational parameters. Multi-slices CT are optional pre-/post-procedure and at 3 years follow-up. All clinical data will be collected and managed by statistical center, clinical endpoint adjudication committee. All imaging modalities data will be collected and analysed by an independent imaging core laboratory.
Participants will receive a single 18-mg oral dose of LY2216684 on Days 1 and 10. Clarithromycin (500 mg) will be administered twice a day (BID) on Days 6 through 13.
The intervention involves an "online escape room teaching" experience, aimed at enhancing participants' cognition, clinical reasoning, self-efficacy, and learning satisfaction. Participants complete a pre-test survey before the "online escape room teaching" session, followed by a post-test and satisfaction survey after the course. The entire game intervention and testing process takes 80-90 minutes. Learning outcomes, including cognition, clinical reasoning, and self-efficacy, are reassessed four weeks later.
The invention provides a flavonoid extract containing schaftoside, which is prepared from raw traditional Chinese medicinal herbal materials medicine raw materials. The invention also relates to the application of the flavonoid extract in treating cerebral ischemia. The invention particularly provides a flavonoid extract prepared from the raw medicinal material of rhizoma arisaematisarisaema tuber raw material medicine and an extraction method thereof. The invention also provides a medicinal composition adopting the extract. The extraction method is simple and practical, and the extraction effect is favorable. The medicinal composition has an obvious determined curative effect, which and has a brand new application in the aspect for treating cerebrovascular diseases.
This is a monocentric, interventional, prospective, comparative, randomized study in 2 parallel groups, single-blind. The study is proposed to the patient during the preoperative anesthetic consultation. The patient and the people carrying out the functional assessments (physiotherapists) will be blinded to the analgesia received, unlike the investigator.

Patients will be included by an anesthesiologist during the preoperative anesthetic consultation. After the Accelerated Rehabilitation After Surgery consultation, they will then be operated on (Day 0) and seen up to 5 times post-operatively over a period of 45 days for the purposes of the study: at 24h, 48h, 72h, discharge from hospital and 45 days post operative. Discharge from hospital occurs during follow-up depending on the patient's condition. These visits will coincide with follow-up consultations with the surgeon as part of the usual management.
A process for the production of liquid or dispersed concentrates comprising a polymer prepared by radical polymerization of acryloyldimethyltaurine, an organic solvent and an emulsifier whereby the polymerization is carried out in a medium and the resulting mixture is mixed with a solvent or solvent mixture and the polymerization medium is removed, optionally at reduced pressure and elevated temperature. A process for the production of concentrates (I) in liquid or dispersed liquid form comprising: (a) 5-80 wt.% of a polymer prepared by radical polymerization of acryloyldimethyltaurine and/or acryloyldimethyltaurates in the presence of one or more of at least one monofunctional radically polymerizable silicon containing substances (A1), at least monofunctional radically polymerizable fluorine containing substances (A2), single or multi-unsaturated, optionally cross-linked macromonomers containing O, N, S or P with a number average mol. wt. of at least 200 -1 X 10 9> g/mole (A3); (b) 20-95 wt.% of an organic solvent or solvent mixture; (c) 0-60 wt.% of an emulsifier and; (d) 0-30 wt.% water whereby the polymerization is carried out in a polymerization medium, optionally with other additives to form a high mol. wt.; the resulting mixture is mixed with a solvent or solvent mixture, optionally emulsifier and/or water whereby the b.pt. of the solvent is at least 10 [deg] C higher than that of the polymerization medium and the polymerization medium is removed, optionally at reduced pressure and elevated temperature. Independent claims are included for: (1) the resulting concentrate (I) and; (2) cosmetic, pharmaceutical or dermatological formulations containing the concentrate (I).
According to one embodiment, an electronic apparatus includes a registration module, a transmission processor, and a reception processor. The registration module registers second data in a first file in a non-volatile storage device. The transmission processor transmits third data which is at least part of the first file to a server. The third data includes data registered in the first file after the data is previously transmitted to the server. The server includes a second file for registering all data transmitted from at least one second electronic apparatus, which corresponds to a user, including the electronic apparatus. The reception processor does not receive the fourth data from the server when only the electronic apparatus corresponds to the user.
The aims of the study are to reveal the possibly natural change of the gut and oral microbiome of GDM patients during pregnancy, and to explorer whether GDM happened during pregnancy are associated with the maternal gut and oral microbiomes. As a perspective cohort study, the researchers will recruit pregnant women in early pregnancy（before 13 gestational weeks）and following the pregnancies till delivery. The stool samples and saliva samples of the recruits will be collected in 9\~14,24\~28 and 32\~37 gestational weeks separately. The investigators will also perform oral examination between 24\~28 weeks and sample subgingival plaque for test. Overall, all samples will be examined use 16S rRNA gene sequencing to analyze microbiome. And part of the samples of GDM patients will be analyzed using metagenomics. Combine with the pregnancy outcomes, the differences of gut and oral microbiome between GDM patients and healthy women will be expected, as well as the natural change during pregnancy.
Young adults (YA) with cancer have unique challenges in coping, and their primary partners may experience burden and low self-efficacy related to caregiving. In this single-arm pilot trial, the investigators shall deliver an eight-session intervention to YAs with cancer and their self-identified partners who provide caregiving. The intervention is founded on principles from cognitive-behavioral therapy and couples-focused interventions, tailored for YA. The aim of the study is to assess the feasibility and acceptability of the intervention, which will inform refinements prior to a larger-scale clinical trial. This study will include 10 YAs and their partner-caregivers (N=20). Participants will complete surveys at baseline and after the intervention, and will be invited to complete optional semi-structured exit interviews.
Unscheduled (breakthrough or intracyclic) bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use. If bleeding persists or occurs after previously regular cycles, check for causes such as pregnancy or malignancy. If pathology and pregnancy are excluded, bleeding irregularities may resolve over time or with a change to a different COC. 

Patient diaries from the clinical trial of norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) showed that on the first cycle of use, 37% of subjects taking norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) had unscheduled bleeding and/ or spotting. From Cycle 2-13, the percent of women with unscheduled bleeding/spotting ranged from 21-31% per cycle. For those women with unscheduled bleeding/spotting, the mean number of days of unscheduled bleeding/spotting was 5.2 in the first cycle of use and ranged from 3.6-4.2 in Cycles 2-13. A total of 15 subjects out of 1,677 (0.9%) discontinued the study prematurely due to metrorrhagia or irregular menstruation. 

Women who are not pregnant and use norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) may not have scheduled (withdrawal) bleeding every cycle or may experience amenorrhea (absence of any bleeding and spotting). The incidence of amenorrhea in the clinical trial increased from 8.1% of the subjects in Cycle 2 to 18.4% by Cycle 13. For those women who had scheduled (withdrawal) bleeding, the average duration of bleeding per cycle in Cycles 2-13 was 3.7 days. 

If the patient has not adhered to the prescribed dosing schedule (missed one or more active tablets or started taking them on a day later than she should have), consider the possibility of pregnancy at the time of the first missed period and take appropriate diagnostic measures. If the patient has adhered to the prescribed regimen and misses two consecutive periods, rule out pregnancy. 

Some women may encounter amenorrhea or oligomenorrhea after stopping COCs, especially when such a condition was pre-existent.